{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:31:34Z","timestamp":1769603494567,"version":"3.49.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>T315I+ Philadelphia chromosome\u2013positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited. We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABLT315I mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with chronic myeloid leukemia were in the chronic phase and 4.5% were in advanced phases. Median overall survival after transplantation was 10.3 months (range 5.7 months to not reached [ie, still alive]) for those with chronic myeloid leukemia in the blast phase and 7.4 months (range 1.4 months to not reached [ie, still alive]) for those with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia but has not yet been reached for those in the chronic and accelerated phases of chronic myeloid leukemia. The occurrence of chronic GVHD had a positive impact on overall survival (P = .047). Transplant-related mortality rates were low. Multivariate analysis identified only blast phase at transplantation (hazard ratio 3.68, P = .0011) and unrelated stem cell donor (hazard ratio 2.98, P = .011) as unfavorable factors. We conclude that allogeneic stem cell transplantation represents a valuable therapeutic tool for eligible patients with BCR-ABLT315I mutation, a tool that may or may not be replaced by third-generation tyrosine kinase inhibitors.<\/jats:p>","DOI":"10.1182\/blood-2011-07-367326","type":"journal-article","created":{"date-parts":[[2011,9,17]],"date-time":"2011-09-17T05:11:34Z","timestamp":1316236294000},"page":"5697-5700","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias"],"prefix":"10.1182","volume":"118","author":[{"given":"Franck Emmanuel","family":"Nicolini","sequence":"first","affiliation":[{"name":"Hematology Department, H\u00f4pital Edouard Herriot, Lyon, France;"},{"name":"French group of CML (Fi-LMC group), Poitiers, France;"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC), Bordeaux, France;"},{"name":"Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Leiden, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz W.","family":"Basak","sequence":"additional","affiliation":[{"name":"Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Leiden, The Netherlands;"},{"name":"Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Molecular Biology Unit, University of Bologna, Bologna, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Molecular Biology Unit, University of Bologna, Bologna, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Knight Cancer Institute, Center for Hematologic Malignancies, Portland, OR;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Jena, Jena, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[{"name":"Department of Hematology, Singapore General Hospital, Singapore; Cancer & Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge H.","family":"Dufva","sequence":"additional","affiliation":[{"name":"Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Rege-Cambrin","sequence":"additional","affiliation":[{"name":"University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Leiden, The Netherlands;"},{"name":"University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[{"name":"Hematology Department, H\u00f4pital Edouard Herriot, Lyon, France;"},{"name":"French group of CML (Fi-LMC group), Poitiers, France;"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC), Bordeaux, France;"},{"name":"Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Leiden, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re","sequence":"additional","affiliation":[{"name":"Hematology Department, H\u00f4pital Edouard Herriot, Lyon, France;"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC), Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Morisset","sequence":"additional","affiliation":[{"name":"Hematology Department, H\u00f4pital Edouard Herriot, Lyon, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[{"name":"French group of CML (Fi-LMC group), Poitiers, France;"},{"name":"Hospices civils de Lyon, Centre Hospitalier Lyon Sud, Laboratory for Hematology and UMR5239, Pierre-B\u00e9nite, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[{"name":"French group of CML (Fi-LMC group), Poitiers, France;"},{"name":"Institut Bergoni\u00e9, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Olavarria","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia, Hospital de Navarra Irunlarrea s\/n, Pamplona Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Merck Research Laboratories, North Wales, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senaka","family":"Peter","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Merck Research Laboratories, North Wales, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Leiden, The Netherlands;"},{"name":"Centre for Haematology, Imperial College London, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"11","key":"2019111808202057400_B1","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107, and BMS 354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"26","key":"2019111808202057400_B2","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111808202057400_B3","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and acute lymphocytic leukaemia after Bcr-Abl mutation-related imatinib failure.","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"15","key":"2019111808202057400_B4","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.25092","article-title":"Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.","volume":"116","author":"Velev","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"2019111808202057400_B5","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"2019111808202057400_B6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"35","key":"2019111808202057400_B7","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808202057400_B8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111808202057400_B9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"issue":"24","key":"2019111808202057400_B10","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111808202057400_B11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC group).","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"2019111808202057400_B12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111808202057400_B13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"2019111808202057400_B14","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404772","article-title":"BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?","volume":"21","author":"Legros","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"2019111808202057400_B15","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2007-06-094508","article-title":"Interferon-\u03b1 or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.","volume":"110","author":"de Lavallade","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111808202057400_B16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3816\/CLML.2010.n.073","article-title":"The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.","volume":"10","author":"Nicolini","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"2019111808202057400_B17","first-page":"267","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation: results of an ongoing multicenter phase 2\/3 study [abstract].","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"issue":"21","key":"2019111808202057400_B18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood.V116.21.210.210","article-title":"A phase I trial (AP 24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings [abstract].","volume":"116","author":"Cortes","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/20\/5697\/1347577\/zh804611005697.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/20\/5697\/1347577\/zh804611005697.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:40:51Z","timestamp":1574084451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/20\/5697\/29791\/Allogeneic-stem-cell-transplantation-for-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,17]]},"references-count":18,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2011,11,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-367326","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,17]]}}}